Addendum
Lutetium vipivotide tetraxetan (prostate cancer) – Addendum to Commission A23-01
Report documents
-
Addendum
Lutetiumvipivotidtetraxetan (Prostatakarzinom) - Addendum zum Auftrag A23-01
Dossier assessment
Indication:
In combination with androgen deprivation therapy with or without androgen receptor pathway inhibition for the treatment of adult patients with progressive prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer who have been treated with androgen receptor pathway inhibition and taxane-based chemotherapy
Result of dossier assessment:
- Patients for whom abiraterone in combination with prednisone or prednisolone, enzalutamide or best supportive care is the most appropriate therapy for the individual patient: after addendum now indication of major added benefit
- Patients for whom cabazitaxel or olaparib is the most appropriate therapy for the individual patient: added benefit not proven
Additional information
Federal Joint Committee (G-BA)
2023-07-06 A G-BA decision was published.
Project details
- Project no.
- A23-46
- Commission
- Commission awarded on 25.05.2023 by the Federal Joint Committee (GBA).
- Report type
- Addendum
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Cancer
- Note
-
If the need for additional work on a project commissioned by the GBA arises during consultations, IQWiG submits an addendum. The subsequent decides on the extent of the added benefit concludes the early benefit assessment.
Connected Projects
-
Dossier assessment
Lutetium vipivotide tetraxetan (prostate cancer) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed